On August 13, 2024, Brian Dorsey, Chief Operating Officer of ARS Pharmaceuticals Inc (NASDAQ:SPRY), sold 30,000 shares of the company’s stock. The transaction was documented in a recent SEC filing. Following this sale, the insider now owns 6,024 shares of the company’s stock.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) is focused on developing novel medicines to improve patients’ lives by treating severe allergic reactions more quickly and effectively. The company’s lead product, epinephrine, is used for the emergency treatment of anaphylactic reactions.
In the past year, Brian Dorsey sold a total of 30,000 shares and did not buy any shares of the company. ARS Pharmaceuticals Inc insider transaction history shows a trend with 6 insider purchases and 28 insider sales in the past year.
ARS Pharmaceuticals Inc. shares traded at $13 on the day of the sale, giving the company a market capitalization of approximately $1.31 billion.
Investors can find more detailed valuation metrics such as the GF value, the price-earnings ratio, the price-sales ratio, the price-book value ratio and the price-free cash flow ratio in the details of the company’s share performance and valuation.
This article created by GuruFocus is intended to provide general insights and does not constitute tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment advice. It does not contain a recommendation to buy or sell any stock and does not take into account any individual investment objectives or financial circumstances. Our goal is to provide long-term, fundamental, data-driven analysis. Note that our analysis may not include the most recent, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in any stocks mentioned here.
This article first appeared on GuruFocus.
